ClinicalTrials.gg
RecruitingNCT07518602Updated Apr 8, 2026

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

A Phase 2 interventional study of Chidamide and Sintilimab in Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Carcinoma, Neuroendocrine with a site in China — 26 open to participants now, 27 under way, 4 of them phase 3. Carcinoma, Neuroendocrine · China.

Planned enrollment
28th of 32
34 · median 80
Started
2026
with 10 others
Phase 2
14 of 39
6 open now
Primary completion
2028-03
later than 20 of 26 live
Registered
31st of 39
by date

Among the 39 studies in Carcinoma, Neuroendocrine with a site in China, this one is the 28th largest by planned enrollment of the 32 interventional ones that give a count, is one of 11 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 20 of the 26 other live ones, and was the 31st registered.

Carcinoma, Neuroendocrine

172 studies on the registry are indexed under Carcinoma, Neuroendocrine; 65 are open to participants now.

Browse Carcinoma, Neuroendocrine studies →

Open to participants now

26 of the 39 studies in Carcinoma, Neuroendocrine with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Carcinoma, Neuroendocrine studies recruiting now, 29 (63%) set no upper age limit and 10 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Carcinoma, Neuroendocrine with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, multicenter phase Ⅱ study to evaluate the therapeutic efficacy and safety of chidamide + sintilimab + bevacizumab in subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy. The primary purpose is to assess the objective response rate (ORR) of chidamide + sintilimab + bevacizumab in the above-mentioned subjects, with a planned enrollment of 34 subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy.

Read the detailed description

This is a single-arm, multicenter phase Ⅱ clinical study. All eligible subjects will receive the unified treatment of chidamide + sintilimab + bevacizumab, with no control group set in the study. The treatment regimen for all enrolled subjects is 200 mg of sintilimab administered via intravenous drip once every 3 weeks (Q3W), 20 mg of chidamide administered orally twice a week (BIW) 30 minutes after meals, and 7.5 mg/kg of bevacizumab administered via intravenous drip once every 3 weeks (Q3W). The administration sequence of the intravenous drugs is as follows: sintilimab is given first with an infusion time of 60±15 minutes, and bevacizumab is administered at least 5 minutes after the completion of sintilimab infusion. The treatment will continue until disease progression, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified in the study protocol, whichever occurs first, with the maximum treatment duration until disease progression. For subjects who are initially judged to have disease progression according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), if their clinical conditions are stable, the investigator will judge whether they can continue to receive the study drug treatment, and the disease progression will be confirmed according to the Immune Response Evaluation Criteria in Solid Tumors (iRECIST) 4\~6 weeks later.

The primary endpoint of this study is the objective response rate (ORR) of chidamide + sintilimab + bevacizumab in the enrolled subjects, defined as the proportion of subjects achieving complete response (CR) or partial response (PR) evaluated by the investigator based on RECIST v1.1. The secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DOR) of the treatment, as well as the safety of chidamide + sintilimab + bevacizumab evaluated by the incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), and changes in vital signs, physical examination results, and laboratory test indicators.

A total of 34 subjects with advanced extrapulmonary neuroendocrine carcinoma who have failed first-line standard therapy will be enrolled in this study. The enrollment criteria require that subjects are pathologically or cytologically confirmed with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinoma, have at least one measurable lesion according to RECIST v1.1, an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0\~1, an expected survival time of ≥12 weeks, and adequate organ and bone marrow function. Subjects with a history of exposure to anti-angiogenic targeted therapy or HDAC inhibitors, uncontrolled severe infections, symptomatic central nervous system metastasis, and other conditions that do not meet the inclusion criteria will be excluded from the study.

Efficacy assessments will be conducted using contrast-enhanced CT or MRI, with examinations covering the chest, abdomen, and pelvis. For subjects with suspected or known central nervous system metastasis, enhanced cranial MRI will be performed at the baseline. Tumor imaging evaluations will be conducted every 6 weeks (±7 days) within 24 weeks after the first dose of the study drug, and every 9 weeks (±7 days) after 24 weeks until the initiation of new anti-tumor therapy, disease progression, withdrawal of informed consent, or death. The primary efficacy analysis of ORR will estimate the proportion of subjects and calculate the 95% exact two-sided confidence interval (CI) using the Clopper Pearson method. For time-to-event indicators such as PFS, OS, and DOR, the Kaplan-Meier method will be used for analysis, and the median time, the rate at each time point, and their 95% CIs will be calculated.

Safety assessments will be conducted throughout the study period, including the screening period, treatment period, and follow-up period. All AEs, TEAEs, AESIs, and SAEs will be graded and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0). Regular laboratory examinations include blood routine, coagulation function, blood biochemistry, myocardial markers, urine routine, fecal routine + occult blood, thyroid function, and viral serological tests. Vital signs, physical examinations, 12-lead electrocardiograms, and echocardiograms will be monitored at each study visit as scheduled. Serious adverse events will be reported by the investigator to the sponsor, drug regulatory authorities, and ethics committee within 24 hours of awareness.

After the termination of study treatment, subjects will undergo a safety follow-up 30 days (±7 days) after the last dose of the study drug, and survival follow-up will be conducted every 90 days (±7 days) after the safety follow-up, which can be completed by telephone follow-up. The survival follow-up will continue until the subject's death or the end of the study to collect information related to overall survival and subsequent anti-tumor therapy.

03

Conditions studied

  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Keywords

  • extrapulmonary neuroendocrine carcinoma
  • chidamide
  • sintilimab
  • bevacizumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed locally advanced, unresectable, or extrapulmonary neuroendocrine carcinoma (NEC).
  2. Failure of standard systemic therapy, with documented disease progression during or after treatment by imaging or clinical evidence (e.g., cytology of new ascites or pleural effusion). Patients who discontinued first-line therapy due to intolerable toxicity are eligible.
  3. At least one per version 1.1.
  4. (ECOG) performance status of 0 or 1.
  5. Able to provide written and comply with study visits and procedures.
  6. Age ≥ 18 years and ≤ 75 years.
  7. ≥ 12 weeks.
  8. Women of and men with female partners of childbearing potential must use effective throughout the treatment period and for 6 months after the last dose of study treatment.
  9. Adequate organ and bone marrow function within 7 days before enrollment, without support treatments (blood products, growth factors, albumin) within 14 days before testing: (ANC) ≥ 1.5 × 10⁹/L; count (PLT) ≥ 100 × 10⁹/L; (HGB) ≥ 9.0 g/dL; serum total (TBIL) ≤ 1.5 × (ULN); /AST ≤ 3.0 × ULN (no liver metastasis) or ≤ 5.0 × ULN (with liver metastasis); serum albumin ≥ 25 g/L; serum creatinine (Cr) ≤ 1.5 × ULN; urine protein \< 2+ or 24-hour urine protein \< 1 g if urine protein ≥ 2+; ≤ 1.5 × ULN and APTT ≤ 1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to any anti-angiogenic therapy or histone deacetylase (HDAC) inhibitor.
  2. Received any drug within 4 weeks before the first dose of study treatment.
  3. Simultaneously participating in another interventional clinical study (observational or follow-up studies are allowed).
  4. Received last dose of anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, embolization, etc.) within 3 weeks before first dose.
  5. Received radiotherapy within 4 weeks before first dose.
  6. Residual radiation-related toxicity (e.g., pneumonitis, hepatitis, enteritis) from prior radiotherapy > 4 weeks before first dose, including symptomatic cases or those requiring .
  7. Received systemic drugs within 4 weeks before first dose, except topical/inhaled corticosteroids or physiological systemic corticosteroids (≤ 10 mg/day prednisone equivalent).
  8. Received or plans to receive within 4 weeks before first dose or during the study.
  9. Underwent major surgery within 4 weeks before first dose, or has unhealed wounds, ulcers, or fractures.
  10. Resolved toxicity from prior anti-tumor therapy not recovered to version 5.0 grade ≤ 1 (except alopecia or non- laboratory abnormalities).
  11. Known symptomatic central nervous system (CNS) or carcinomatous meningitis. Patients with treated and stable for ≥ 4 weeks and neurological symptoms recovered to grade ≤ 1 are allowed.
  12. Active disease requiring systemic therapy within 2 years before first dose; or primary immunodeficiency. Replacement therapy (e.g., thyroid hormone, insulin) is permitted.
  13. Active tuberculosis, or anti-tuberculosis treatment within 1 year before first dose.
  14. Interstitial lung disease requiring corticosteroid treatment.
  15. Active (HBsAg positive and HBV DNA ≥ 200 IU/mL) or active (HCV antibody positive and HCV RNA positive).
  16. Known infection or syphilis.
  17. Severe uncontrolled active infection, including hospitalization for infection within 4 weeks before first dose.
  18. Significant malnutrition requiring intravenous nutrition, unless corrected for > 4 weeks before first dose.
  19. Symptomatic congestive heart failure ( class II-IV), or symptomatic/uncontrolled arrhythmia.
  20. Uncontrolled arterial hypertension despite optimal treatment (systolic BP ≥ 150 mmHg or diastolic BP ≥ 100 mmHg).
  21. Any arterial thromboembolic event (myocardial infarction, pulmonary embolism, unstable angina) within 6 months before enrollment.
  22. History of deep vein thrombosis or other severe thromboembolism within 3 months before enrollment (catheter-related or superficial vein thrombosis excluded).
  23. Hepatic encephalopathy, hepatorenal syndrome, or B or C cirrhosis.
  24. History of gastrointestinal perforation/fistula, peptic ulcer, bowel obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, intra-abdominal abscess, or chronic diarrhea within 6 months before enrollment; or intestinal stent placement.
  25. Uncontrolled metabolic disorders or other severe medical conditions that may increase study risk or confound result interpretation.
  26. Hereditary bleeding tendency or coagulation disorder.
  27. Any life-threatening bleeding event within 3 months before enrollment (requiring transfusion, surgery, or continuous treatment).
  28. High bleeding risk per investigator assessment: severe esophageal/gastric varices, intermittent bleeding (e.g., hematochezia, hemoptysis).
  29. Cerebrovascular accident (including ) within 6 months before enrollment.
  30. Use of aspirin (> 325 mg/day) or other inhibitors for 10 consecutive days within 10 days before first dose.
  31. Use of oral or parenteral anticoagulants or thrombolytics for 10 consecutive days within 10 days before first dose (prophylactic anticoagulation allowed).
  32. Symptomatic or drainable pleural effusion, ascites, or pericardial effusion (only small asymptomatic effusions by imaging are allowed).
  33. History of other primary , except: Malignancy in complete remission for ≥ 2 years without treatment during study;adequately treated non-melanoma skin cancer or carcinoma in situ with no evidence of recurrence.
  34. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  35. Known to any monoclonal antibody component or study drug .
  36. Pregnant or breastfeeding female patients.
  37. History of alcoholism or drug abuse.
  38. Any other acute or chronic disease, psychiatric disorder, or laboratory abnormality that, in the investigator's opinion, increases study risk or interferes with result interpretation.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    CAP

    chidamide + sintilimab + bevacizumab

    Drug: Chidamide · Drug: Sintilimab · Drug: Bevacizumab

Interventions

  • DrugTucidinostatStudies of TucidinostatTucidinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    20 mg of chidamide administered orally twice a week (BIW) 30 minutes after meals

  • 200 mg of sintilimab administered via intravenous drip once every 3 weeks (Q3W)

  • 7.5 mg/kg of bevacizumab administered via intravenous drip once every 3 weeks (Q3W)

06

What researchers measure

Primary outcomes

  1. ORR

    The primary endpoint of this study is the objective response rate (ORR) of chidamide + sintilimab + bevacizumab in the enrolled subjects, defined as the proportion of subjects achieving complete response (CR) or partial response (PR) evaluated by the investigator based on RECIST v1.1.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

Secondary outcomes

  1. PFS

    Progression-free survival (PFS), defined as the time from the first study treatment to disease progression (per RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

  2. OS

    Overall survival (OS), defined as the time from the first study treatment to death from any cause.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

  3. DCR

    Disease control rate (DCR), defined as the proportion of subjects achieving complete response (CR), partial response (PR), or stable disease (SD) evaluated by the investigator based on RECIST v1.1.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

  4. DOR

    Duration of response (DOR), defined as the time from first documentation of objective response (CR/PR) to disease progression or death, whichever occurs first.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

  5. Incidence of Adverse Events (AEs)

    Safety evaluated by incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), changes in vital signs, physical examination findings, and laboratory test parameters.

    Time frame: From date of first study treatment until disease progression, up to approximately 37 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2028, 24 months later.

Of 43 phase 2 interventional studies under Carcinoma, Neuroendocrine, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 91. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 8, 2026
StartEst.
Mar 27, 2026
Primary completionEst.
Mar 27, 2028
CompletionEst.
Sep 27, 2028
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07518602
Responsible party
Feng Wang (Professor, Department Director, Sun Yat-sen University) — Principal investigator
First posted
Apr 8, 2026
Start date
Mar 27, 2026 (estimated)
Primary completion
Mar 27, 2028 (estimated)
Completion
Sep 27, 2028 (estimated)
Last update
Apr 8, 2026

Study contacts

Feng Wang, MD, PhD
Contact
wangfeng@sysucc.org.cn
+86 020 87343795
Zhiqiang Wang, MD, PhD
Contact
wangzhq@sysucc.org.cn
+86 02087340776
Feng Wang, MD, PhD
principal investigator · Sun Yat-sen Univesity Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tucidinostat · Sintilimab · Bevacizumab

Start the discussion